|Articles|February 21, 2017
FDA Awards ICON with Project Validating PROs
ICON plc announced that the US FDA has awarded the company with a project validating three Patient Reported Outcomes instruments that will measure clinical endpoints in antibacterial drug trials.
Advertisement
ICON plc announced that the US FDA has awarded the company with a project validating three Patient Reported Outcomes instruments that will measure clinical endpoints in antibacterial drug trials.
Read the full release here
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
Ensuring Digital Trial Platforms Work for Underserved CommunitiesSeptember 10th 2025
eClinical Technology: Misconceptions, Challenges, and OpportunitiesSeptember 9th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Investigational PD-L1 x VEGF-A Bispecific Antibody Demonstrates Strong Overall Response Rate in Phase II Small Cell Lung Cancer Trial
2
Investigational OX40-Targetting T-Cell Therapy Shows Durable Efficacy Treating Atopic Dermatitis in Phase III Trial
3
eClinical Technology: Misconceptions, Challenges, and Opportunities
4
AstraZeneca’s Tagrisso Shows Landmark Overall Survival Benefit in Non-Small Cell Lung Cancer
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
